Company Profile
Delcath Systems Stock Price, News & Catalysts
- Ticker:
- DCTH
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
17.05 USD (+1.91%)
Close
Last updated: August 17, 2026
364M USD
Market cap
Why the stock is moving
As of Aug 17, 2026, DCTH closed up 1.91% at $17.05. No new same-company headline was identified in the current news window.
Company overview
Interventional Oncology
Delcath Systems develops liver-directed therapies for primary and metastatic liver cancers. Its technology isolates hepatic circulation so high-dose chemotherapy can be delivered to the liver while limiting systemic exposure.
HEPZATO KIT
HEPZATO KIT combines melphalan with the company's percutaneous hepatic-perfusion system. It is approved in the United States for selected adults with unresectable hepatic-dominant metastatic uveal melanoma. CHEMOSAT is the European commercial version of Delcath's hepatic-delivery platform. The company supports adoption through treatment-center activation, clinician training and procedure-based consumable sales.
Future catalysts
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Delcath Systems (DCTH)?
Delcath Systems (DCTH) most recently closed at 17.05 USD, a +1.91% move versus the previous session.
What is the market cap of Delcath Systems (DCTH)?
Delcath Systems currently has a market capitalization of 364M USD on BioPharmSignal.
What does Delcath Systems do?
Interventional Oncology Delcath Systems develops liver-directed therapies for primary and metastatic liver cancers. Its technology isolates hepatic circulation so high-dose chemotherapy can be delivered to the liver while limiting systemic exposure. HEPZATO KIT HEPZATO KIT combines melphalan with the company's percutaneous hepatic-perfusion system. It is...
On which exchange is DCTH stock listed?
Delcath Systems (DCTH) is associated with NASDAQ, United States, Biopharma.
What is Interventional?
Interventional Oncology Delcath Systems develops liver-directed therapies for primary and metastatic liver cancers.
Which conditions is Delcath Systems targeting with Interventional?
Delcath Systems is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
What is Oncology?
Interventional Oncology Delcath Systems develops liver-directed therapies for primary and metastatic liver cancers.
What is Delcath?
Interventional Oncology Delcath Systems develops liver-directed therapies for primary and metastatic liver cancers.